At Extreme Investor Network, we bring you the latest and most cutting-edge insights in the business world. Today, we are thrilled to share some groundbreaking news from Moderna, one of the leading biotech companies in the world.
Moderna announced on Monday that its combination vaccine targeting both Covid-19 and the flu has shown to be more effective than existing standalone shots for these viruses in a late-stage trial. This development puts Moderna in the lead over rivals such as Pfizer and Novavax.
The company plans to file for regulatory approval for its combination jab this summer in the U.S., with hopes of entering the market by 2025. This news comes at a critical time when vaccination rates against Covid are declining, making it more important than ever to have convenient and effective solutions to protect against respiratory viruses.
Moderna’s mRNA combination shot, named mRNA-1083, combines the company’s vaccine candidate for seasonal influenza with a next-generation version of its Covid shot. The results from separate phase three trials for both vaccines have been positive, showing increased immune responses against influenza strains and the Covid omicron variant XBB.1.5.
In addition to targeting the flu and Covid, Moderna is also working on a combination shot for the flu and RSV, as well as a vaccine that targets all three respiratory viruses: Covid, flu, and RSV. The company’s dedication to innovation and tackling multiple respiratory threats sets it apart in the biotech industry.
While Moderna leads the way in developing combination shots, Pfizer and Novavax are also working on similar vaccines in late-stage trials. However, Moderna’s mRNA technology and proven track record in vaccine development give it a competitive edge in this space.
Stay tuned to Extreme Investor Network for more exclusive insights and analysis on the latest business news and trends. Our commitment is to provide you with valuable information that will help you make informed investment decisions. Trust us to be your go-to source for all things related to the business world.